[{"id":"1ee70366-b7a8-4f46-abc0-90483806c589","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744652","created_at":"2021-01-18T07:38:47.984Z","updated_at":"2024-07-02T16:35:46.306Z","phase":"Phase 1","brief_title":"Dasatinib and Crizotinib in Advanced Cancer","source_id_and_acronym":"NCT01744652","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF • ALK • MET • CDKN2A • DDR2 • CTGF","pipe":" | ","alterations":" BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification","tags":["BRAF • ALK • MET • CDKN2A • DDR2 • CTGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • MET amplification • MET overexpression • CDKN2A mutation • MET mutation • ALK translocation • ALK amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-06-07"}]